UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): April 8, 2003
HEMACARE CORPORATION
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
000-15223 95-3280412
(Commission File No.) (IRS Employer Identification No.)
21101 Oxnard Street
Woodland Hills, CA 91367
(Address of principal executive offices and Zip Code)
Registrant's telephone number, including area code: (818) 226-1968
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMAITON
AND EXHIBITS
(c) Exhibits
Exhibit Number Description
-------------- ---------------------------------------------
99.1 Press Release issued by HemaCare Corporation,
dated April 8, 2003
ITEM 9. REGULATION FD DISCLOSURE
The text of a press release dated April 8, 2003, issued by
HemaCare Corporation ("HemaCare") regarding the development
of a new liquid intravenous gamma globulin (IVIG) manufacturing
process is attached as Exhibit 99.1 hereto and is incorporated
by reference herein. However, there can be no assurance that
HemaCare will be successful in obtaining a U.S. patent for the
IVIG manufacturing process or that HemaCare will be able to
license this process to commercial fractionators.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date: April 8, 2003 HEMACARE CORPORATION
/s/ Judi Irving
--------------------------
Judi Irving,
Chief Executive Officer
EXHIBIT INDEX
Exhibit Number Description
-------------- ----------------------------------------------
99.1 Press Release issued by HemaCare Corporation,
dated April 8, 2003.